Celecoxib Capsules
Pre-Solicitation Posted
This opportunity was awarded. See the award notice from , or the latest solicitation from .
- Solicitation number
- SPE2D2-25-R-0021
- Agency
-
Medical Supply Chain
Troop Support, Department of Defense
- Responses due
- Not on record
- Set-aside
- No set-aside
Opportunity facts
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
Notice details come from SAM.gov. Updated .
About this opportunity
The Defense Logistics Agency Troop Support Medical is planning to issue a solicitation for a national requirements contract for Celecoxib Capsules in various strengths and bottle configurations, including 50 MG capsules in 60 count bottles, 100 MG capsules in 100 and 500 count bottles, 200 MG capsules in 100 and 500 count bottles, and 400 MG capsules in 60 count bottles. This procurement will establish a national supply source for Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons customers through the DLA and VA prime vendor programs. The acquisition will be unrestricted and fully competitive, classified as a commercial item procurement under FAR Part 12. The contract structure will be a firm-fixed price requirements type with a one-year base period and four one-year option periods. The current projected solicitation date is September 2025, though DLA reserves the right to issue the solicitation before or after this projected timeframe. Interested parties should contact Ryan Guarnere at 445-737-1729 or Ryan.Guarnere@dla.mil for questions and are advised to set up automated notifications for pre-solicitation or solicitation changes.
This opportunity does not utilize any set-aside designations and will be open to all qualified sources for proposal submission. No incumbent contractors or current providers are specifically mentioned in the pre-solicitation notice. While specific award values or budget ranges are not disclosed, the solicitation will include annual usage estimates in the Schedule of Supplies section when released. The contract covers multiple pharmaceutical strengths ranging from 50 MG to 400 MG capsules with varying bottle quantities from 60 to 500 count configurations. The five-year total contract duration includes the initial base year plus four option years, providing potential for extended supplier relationships. Solicitation documents will be made available through both the DLA Bid Board System (DIBBS) and Sam.gov when formally released.
Notice text
The Defense Logistics Agency is planning to issue a solicitation for a national requirements contract for Celecoxib Capsules. Procurement details follow.
Celecoxib 50 MG capsules in 60 count bottles, 100 MG capsules in 100 and 500 count bottles, 200 MG capsules in 100 and 500 count bottles, and 400 MG capsules in 60 count bottles. This will be an unrestricted and fully competitive acquisition. The contract will be a firm-fixed price, requirements type contract with a one-year base and four one-year options. A contract resulting from this solicitation will establish a national supply source, in accordance with FAR 52.216-21 (Requirements), to provide the items listed in the schedule for purchase by Department of Defense, Department of Veterans Affairs, Indian Health Service and Bureau of Prisons customers through the DLA and VA prime vendor programs. The annual usage estimates will be provided in the Schedule of Supplies section of the solicitation. This is a commercial item and will be solicited using FAR part 12. All sources may submit a proposal which shall be considered by the agency.
A copy of the solicitation will be posted to the DLA Bid Board System (DIBBS) at https://www.dibbs.bsm.dla.mil and Sam.gov at https://sam.gov/. Interested parties should contact Ryan Guarnere (445-737-1729) (Ryan.Guarnere@dla.mil) for any questions/comments. Interested parties are further advised to set up automated notifications of pre-solicitation or solicitation changes through this website. The current projected solicitation date is September of 2025. DLA reserves the right to issue the solicitation before or after the projected solicitation date.
Notice history
| Notice | Type | Posted |
|---|---|---|
| Celecoxib Capsules | Award Notice | |
| Celecoxib Capsules | Solicitation | |
| This notice | Pre-Solicitation |
Similar open opportunities
| Opportunity | Agency | Set-aside | Responses due |
|---|---|---|---|
| Methylphenidate ER | Medical Supply Chain | No set-aside | |
| 6505--Imatinib Tablets | National Acquisition Center | No set-aside | |
| Epinephrine Injector | Medical Supply Chain | No set-aside |
On GovTribe
Work this opportunity
- Track it in your pipeline
- Find teaming partners
- Similar opportunities
- Ask GovTribe AI about this opportunity